Cytokine profile in the patients with bronchial asthma of different endotypes after vaccination against pneumococcus

Numerous observations of patients with bronchial asthma (BA) vaccinated against pneumococcal infection have revealed a significantly reduced frequency of exacerbations and hospitalisations after immunisation. Several studies have considered pneumococcal vaccines potential immunoregulators that may improve the clinical course of BA via modulation of the immune response. However, interpretation of these results has serious limitations due to heterogeneity of primary disease and differences in vaccine preparations. The aim of the present study was to perform a comparative analysis of the key cytokines levels which characterize development of distinct BA endotypes in patients following administration of conjugated pneumococcal vaccine. We have analyzed serum samples (n = 31) from patients with BA immunized by PCV13 (Prevenar 13), using ELISA technique, for Th1/Th2/Treg cytokines (IFNγ, IL-4, IL-6, IL-8, IL-10, IL-18, TNFα, and MCP-1), and total IgE level. The time points of sampling were as follows: initial terms, 6 weeks, 6 and 12 months after vaccination.
The results of the study indicate that vaccination against pneumococcal infection using a PCV13 in patients with BA was accompanied by high clinical efficacy, regardless of the disease endotype. This finding was evidenced by a decreased number of BA exacerbations in the patients, and an increased number of non-hospitalized BA patients during 1 year of observation. The clustering of patients according to their inflammatory profile enabled us to detect specific patterns of the cytokine profile. These changes included a statistically significant increase in the concentration of IFNγ in blood serum at 6 weeks after immunisation in the patients with the T2-“high” asthma endotype. Statistically significant changes were observed in patients with atopy and elevated total IgE levels in serum, who exhibited a peak increase in IFNγ concentration, also 6 weeks after vaccination. Conversely, no significant changes in cytokine levels were observed in patients with T2-“low” asthma endotype within a year after vaccination. The results of the study demonstrate that IFNγ plays a significant role in the potential adjustment of immunity in the patients with T2-«high» asthma endotype following immunisation with a pneumococcal conjugate vaccine.

1. Andreeva N.P., Protasov A.V., Kostinova T.A., Lezhenina S.V. Effect of Vaccination against Pneumococcal Infection and Influenza on the Clinical Course of Bronchial Asthma. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2019, Vol. 18, no. 4, pp. 93-100. (In Russ.)

2. Kraposhina A.Yu., Sobko E.A., Demko I.V., Katser A.B., Kazmerchuk O.V., Abramov Yu.I. Modern Understanding of Severe Bronchial Asthma. Arkhiv vnutrenney meditsiny = Russian Archive of Internal Medicine, 2022, Vol. 12, no. 2, pp. 113-122. (In Russ.)

3. Akar-Ghibril N., Casale T., Custovic A., Phipatanakul W. Allergic endotypes and phenotypes of asthma. J. Allergy Clin. Immunol. Pract., 2020, Vol. 8, no. 2, pp. 429-440.

4. Finkelman F.D., Hogan S.P., Hershey G.K.K., Rothenberg M.E., Wills-Karp M. Importance of cytokines in murine allergic airway disease and human asthma. J. Immunol., 2010, Vol. 184, no. 4, pp. 1663-1674.

5. Fitzpatrick A.M., Chipps B.E., Holguin F., Woodruff P.G. T2-“low” asthma: overview and management strategies. J. Allergy Clin. Immunol. Pract., 2020, Vol. 8, no. 2, pp. 452-463.

6. GINA. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2023. Available at: https://ginasthma.org/2023-gina-main-report/. (Access date: March 26, 2024).

7. Jung J.A., Kita H., Dhillon R., Jacobson R.M., Nahm M.H., Park M., Tsigrelis C., Juhn Y.J. Influence of asthma status on serotype-specific pneumococcal antibody levels. Postgrad. Med., 2010, Vol. 122, pp. 116-124.

8. Khan A.Q., Shen Y., Wu Z.Q., Wynn T.A., Snapper C.M. Endogenous pro- and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae. Infect. Immun., 2002, Vol. 70, pp. 749-761.

9. Kim B.G., Ghosh P., Ahn S., Rhee D.K. Pneumococcal pep27 mutant immunization suppresses allergic asthma in mice. Biochem. Biophys. Res. Commun., 2019, Vol. 514, no. 1, pp. 210-216.

10. Kuruvilla M.E., Lee F.E.H., Lee G.B. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clinic. Rev. Allerg. Immunol., 2019, Vol. 56, no. 2, pp. 219-233.

11. Lambrecht B.N., Hammad H. Asthma: The importance of dysregulated barrier immunity. Eur. J. Immunol., 2013, Vol. 43, pp. 3125-3137.

12. Lee T.A., Weaver F.M., Weiss K.B. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Intern. Med., 2007, Vol. 22, no. 1, pp. 62-67.

13. Murdoch J.R., Lloyd C.M. Chronic inflammation and asthma. Mutat. Res., 2010, Vol. 690, no. 1-2, pp. 24-39.

14. Pesek R., Lockey R. Vaccination of adults with asthma and COPD. Allergy, 2011, Vol. 66, no. 1, pp. 25-31

15. Preston J.A., Essilfie A.-T., Horvat J.C., Wade M.A., Beagley K.W., Gibson P.G., Foster P.S., Hansbro P.M. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae. Vaccine, 2007, Vol. 25, no. 48, pp. 8154-8162.

16. Protasov A.D., Kostinov M.P., Zhestkov A.V., Gorbachev D.O., Kostinov A.M., Elner M.E., Kozina T.A. Changes in sputum microbiocenosis and clinical pattern under different vaccination protocols for pneumococcal infection in patients with bronchial asthma. Global J. Respir. Care, 2022, Vol. 8, pp. 18-27.

17. Samitas K., Zervas E., Gaga M. T2-low asthma: current approach to diagnosis and therapy. Curr. Opin. Pulm. Med., 2017, Vol. 23, no. 1, pp. 48-55.

18. Thorburn A.N., Foster P.S., Gibson P.G., Hansbro P.M. Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J. Immunol., 2012, Vol. 188, no. 9, pp. 4611-4620.

19. Thorburn A.N., O’Sullivan B.J., Thomas R., Kumar R.K., Foster P.S., Gibson P.G., Hansbro P.M. Pneumococcal conjugate vaccine-induced regulatory T cells suppress the development of allergic airways disease. Thorax, 2010, Vol. 65, no. 12, pp. 1053-1060.

20. Zhang L., Gao H., Yang T., Yang B., Jiang X., Wang L., Fu Z. Infant 7-valent pneumococcal conjugate vaccine immunization alters young adulthood CD4+ T cell subsets in allergic airway disease mouse model. Vaccine, 2014, Vol. 32, no. 18, pp. 2079-2085.

21. Zhao H., Jung J.A., Briles D.E., Kita H., Tsigrelis C., Juhn Y.J. Asthma and antibodies to pneumococcal virulence proteins. Infection, 2013, Vol. 41, no. 5, pp. 927-934.